ZURICH, Sept 10 (Reuters) - Swiss drugmaker Novartis (NOVN.VX) has won its first approval for multiple sclerosis (MS) tablet Gilenya in Russia, raising hopes of U.S. Food and Drug Administration (FDA) approval later this month.
ZURICH, Sept 10 (Reuters) - Swiss drugmaker Novartis (NOVN.VX) has won its first approval for multiple sclerosis (MS) tablet Gilenya in Russia, raising hopes of U.S. Food and Drug Administration (FDA) approval later this month.
